| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
SNU-0039 targets β-amyloid (Aβ) peptides, specifically inhibiting the aggregation of monomeric Aβ(1-42) into toxic fibrils and inducing the disaggregation of pre-formed Aβ42 fibrils. By preventing Aβ aggregation and promoting fibril disassembly, the compound aims to reduce amyloid plaque formation, a hallmark of Alzheimer's disease pathology.
|
|---|---|
| ln Vitro |
MDR-1339 is an Aβ aggregation inhibitor that modestly inhibits CYP2C8 (IC50, 31.4 μM) but has no discernible inhibitory impact on a set of CYP isoenzymes. MDR-1339 (3.1-50 μM) depolymerizes Aβ fibrils and inhibits Aβ aggregation formation in a dose-dependent manner. Additionally, MDR-1339 (1.5–10 μM) shields cells from the toxicity caused by Aβ [1].
SNU-0039 inhibits aggregation of monomeric Aβ(1-42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 μM. The compound's ability to both prevent fibril formation and promote existing fibril disassembly demonstrates its dual mechanism of action against amyloid pathology. |
| ln Vivo |
In a mouse model of Alzheimer's disease (AD), MDR-1339 (0.1-10 mg/kg, orally) with an ED50 of 0.19 mg/kg dose-dependently restores passive avoidance reflexes. MDR-1339, given orally to APP/PS1 mice every day for eight weeks at doses of 30 and 100 mg/kg, dramatically enhanced spontaneous alternation and decreased Aβ1-40 and Aβ1-42 levels [1].
Specific in vivo efficacy data for SNU-0039 are not extensively detailed in standard reference sources. As an orally bioavailable and blood-brain barrier permeable Aβ aggregation inhibitor, it is expected to show efficacy in animal models of Alzheimer's disease. Studies in transgenic mouse models of amyloidosis would be required to fully characterize its in vivo effects on plaque burden and cognitive function. |
| Enzyme Assay |
SNU-0039's inhibition of Aβ aggregation can be assessed using in vitro Thioflavin T (ThT) fluorescence assays. Aβ(1-42) peptide is incubated with increasing concentrations of SNU-0039 at 37°C for a defined period. ThT fluorescence is measured at excitation/emission wavelengths of 440/490 nm to monitor fibril formation. For disaggregation studies, pre-formed Aβ42 fibrils are incubated with SNU-0039, and the decrease in ThT fluorescence is measured.
|
| Cell Assay |
The cellular activity of SNU-0039 is evaluated in neuronal cell cultures or primary neurons exposed to Aβ oligomers. Cells are treated with Aβ in the presence or absence of increasing concentrations of SNU-0039. Cell viability is assessed using MTT or LDH release assays. Aβ-induced neurotoxicity, oxidative stress, and apoptosis markers are measured to evaluate the protective effects of the compound.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for SNU-0039 are not extensively detailed in standard reference sources. For evaluating its anti-Alzheimer's activity, SNU-0039 would be administered orally to transgenic mouse models of amyloidosis (e.g., APP/PS1 mice). Amyloid plaque burden, Aβ levels in brain and plasma, neuroinflammation markers, and cognitive function (using Morris water maze or novel object recognition tests) would be assessed.
|
| ADME/Pharmacokinetics |
SNU-0039 (DWK-133) has a molecular formula of C20H22O4 and a molecular weight of 326.39 g/mol. It is orally bioavailable and blood-brain barrier permeable. Specific pharmacokinetic parameters such as half-life, bioavailability, and plasma protein binding are not extensively detailed in standard reference sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SNU-0039 is not extensively documented. As an orally bioavailable compound being developed for Alzheimer's disease, its safety profile would be established through standard preclinical toxicology studies. Specific LD50 values and organ-specific toxicity data are not readily available.
|
| References | |
| Additional Infomation |
SNU-0039 (CAS# 1018946-38-7) is also known as DWK-133. It is an orally bioavailable inhibitor of β-amyloid protein aggregation with potential as an anti-Alzheimer's agent. The compound inhibits Aβ(1-42) aggregation and induces disaggregation of Aβ42 fibrils in vitro at concentrations of 3.1-50 μM. Related compound DWK-1339 (MDR-1339) is a brain-penetrant Aβ aggregation inhibitor.
|
| Molecular Formula |
C20H22O4
|
|---|---|
| Molecular Weight |
326.39
|
| Exact Mass |
326.152
|
| CAS # |
1018946-38-7
|
| Related CAS # |
1018946-38-7;
|
| PubChem CID |
24764491
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.696
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CUEPJIGXQLIOIK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H22O4/c1-21-10-4-5-14-6-8-17-16(11-14)13-19(24-17)15-7-9-18(22-2)20(12-15)23-3/h6-9,11-13H,4-5,10H2,1-3H3
|
| Chemical Name |
2-(3,4-Dimethoxyphenyl)-5-(3-methoxypropyl) benzofuran
|
| Synonyms |
SNU0039 DWK1339SNU 0039 DWK 1339SNU-0039 DWK-1339
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~153.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.66 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0638 mL | 15.3191 mL | 30.6382 mL | |
| 5 mM | 0.6128 mL | 3.0638 mL | 6.1276 mL | |
| 10 mM | 0.3064 mL | 1.5319 mL | 3.0638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA